Research programme: dry eye syndrome gene therapy - Clear Solutions Biotech/Laboratorios Sophia
Latest Information Update: 06 Sep 2006
At a glance
- Originator Clear Solutions Biotech; Laboratorios Sophia
- Developer Clear Solutions Biotech
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 06 Sep 2006 Discontinued - Preclinical for Dry eyes in USA (unspecified route)
- 28 Apr 2000 New profile
- 28 Apr 2000 Preclinical development for Dry eyes in USA (Unknown route)